These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
352 related articles for article (PubMed ID: 35045883)
1. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Hu C; Xia R; Zhang X; Li T; Ye Y; Li G; He R; Li Z; Lin Q; Zheng S; Chen R Mol Cancer; 2022 Jan; 21(1):24. PubMed ID: 35045883 [TBL] [Abstract][Full Text] [Related]
2. Cancer-associated fibroblast-derived circFARP1 modulates non-small cell lung cancer invasion and metastasis through the circFARP1/miR-338-3p/SOX4 axis. Zou W; Li Y; Zhang J; Yang R; Yan Y; Zhang X; Yan L; Zhang Z; Zhang X; Chen J Clin Exp Pharmacol Physiol; 2024 Oct; 51(10):e13914. PubMed ID: 39139001 [TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Qi R; Bai Y; Li K; Liu N; Xu Y; Dal E; Wang Y; Lin R; Wang H; Liu Z; Li X; Wang X; Shi B Drug Resist Updat; 2023 May; 68():100960. PubMed ID: 37003125 [TBL] [Abstract][Full Text] [Related]
4. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. Zhang L; Yao J; Li W; Zhang C Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403 [TBL] [Abstract][Full Text] [Related]
5. Cancer-associated fibroblasts promote stemness maintenance and gemcitabine resistance via HIF-1α/miR-21 axis under hypoxic conditions in pancreatic cancer. Deng K; Zou F; Xu J; Xu D; Luo Z Mol Carcinog; 2024 Mar; 63(3):524-537. PubMed ID: 38197482 [TBL] [Abstract][Full Text] [Related]
6. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Huang W; Hu X; He X; Pan D; Huang Z; Gu Z; Huang G; Wang P; Cui C; Fan Y Drug Resist Updat; 2024 May; 74():101079. PubMed ID: 38518727 [TBL] [Abstract][Full Text] [Related]
7. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma. Chen ZW; Hu JF; Wang ZW; Liao CY; Kang FP; Lin CF; Huang Y; Huang L; Tian YF; Chen S J Exp Clin Cancer Res; 2022 Apr; 41(1):153. PubMed ID: 35459186 [TBL] [Abstract][Full Text] [Related]
8. hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Xu L; Ma X; Zhang X; Zhang C; Zhang Y; Gong S; Wu N; Zhang P; Feng X; Guo J; Zhao M; Ren Z; Zhang P Mol Cancer; 2023 Dec; 22(1):195. PubMed ID: 38044421 [TBL] [Abstract][Full Text] [Related]
9. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Fang Y; Zhou W; Rong Y; Kuang T; Xu X; Wu W; Wang D; Lou W Exp Cell Res; 2019 Oct; 383(1):111543. PubMed ID: 31374207 [TBL] [Abstract][Full Text] [Related]
10. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma. Ma L; Fan Z; Du G; Wang H Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935 [TBL] [Abstract][Full Text] [Related]
11. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism. Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382 [TBL] [Abstract][Full Text] [Related]
12. Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer. Yu S; Wang M; Zhang H; Guo X; Qin R J Cell Mol Med; 2024 Jun; 28(12):e18444. PubMed ID: 38924205 [TBL] [Abstract][Full Text] [Related]
13. Combination of RUNX1 inhibitor and gemcitabine mitigates chemo-resistance in pancreatic ductal adenocarcinoma by modulating BiP/PERK/eIF2α-axis-mediated endoplasmic reticulum stress. She C; Wu C; Guo W; Xie Y; Li S; Liu W; Xu C; Li H; Cao P; Yang Y; Wang X; Chang A; Feng Y; Hao J J Exp Clin Cancer Res; 2023 Sep; 42(1):238. PubMed ID: 37697370 [TBL] [Abstract][Full Text] [Related]
14. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK. Toste PA; Nguyen AH; Kadera BE; Duong M; Wu N; Gawlas I; Tran LM; Bikhchandani M; Li L; Patel SG; Dawson DW; Donahue TR Mol Cancer Res; 2016 May; 14(5):437-47. PubMed ID: 26979711 [TBL] [Abstract][Full Text] [Related]
16. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594 [TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Wei L; Ye H; Li G; Lu Y; Zhou Q; Zheng S; Lin Q; Liu Y; Li Z; Chen R Cell Death Dis; 2018 Oct; 9(11):1065. PubMed ID: 30337520 [TBL] [Abstract][Full Text] [Related]
18. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn. Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840 [TBL] [Abstract][Full Text] [Related]
19. Upregulated circular RNA circ_0007534 indicates an unfavorable prognosis in pancreatic ductal adenocarcinoma and regulates cell proliferation, apoptosis, and invasion by sponging miR-625 and miR-892b. Hao L; Rong W; Bai L; Cui H; Zhang S; Li Y; Chen D; Meng X J Cell Biochem; 2019 Mar; 120(3):3780-3789. PubMed ID: 30382592 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]